Shopping Cart
- Remove All
Your shopping cart is currently empty
GSK2033 is an antagonist of LXR (pIC50s: 7 and 7.4 for LXRα or LXRβ, respectively).

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $44 | In Stock | |
| 5 mg | $97 | In Stock | |
| 10 mg | $163 | In Stock | |
| 25 mg | $270 | In Stock | |
| 50 mg | $432 | In Stock | |
| 100 mg | $693 | In Stock | |
| 500 mg | $1,560 | In Stock |
| Description | GSK2033 is an antagonist of LXR (pIC50s: 7 and 7.4 for LXRα or LXRβ, respectively). |
| Targets&IC50 | LXRβ:7.4(pic50), LXRα:7 (pic50) |
| In vitro | GSK2033 dose-dependently inhibits basal transcription in full-length LXRα or full-length LXRβ cotransfection assays (IC50s: 17 nM and 9 nM, respectively). GSK2033 also effectively inhibits the transcription of an ABCA1 driven luciferase reporter dose-dependently (IC50s: 52 nM for LXRα and 10 nM for LXRβ). GSK2033 also suppresses the expression of both of fatty acid synthase (FASN) and SREBP1[2]. |
| In vivo | GSK2033 (one month) treatment, does not have obviously effects on hepatic triglyceride levels. GSK2033 treatment also have no effects on plasma triglyceride levels[2]. |
| Molecular Weight | 591.66 |
| Formula | C29H28F3NO5S2 |
| Cas No. | 1221277-90-2 |
| Smiles | Cc1cc(C)c(c(C)c1)S(=O)(=O)N(Cc1ccc(o1)C(F)(F)F)Cc1ccc(cc1)-c1cccc(c1)S(C)(=O)=O |
| Relative Density. | no data available |
| Color | Yellow |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO: < 1 mg/mL (insoluble or slightly soluble), Sonication and heating are recommended. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.